inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at time of screening who is being treated for covid-19. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (chest x-ray, computed tomography (ct) scan, etc.). 4. pao2/fio2 ratio \> 300 to ≤ 450 mmhg (i.e., arterial oxygen in mmhg divided by fraction inspired oxygen concentration \[e.g., 0.21 for room air\]) 5. any one of the following related to covid-19: i. ferritin \> 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) \> 300 units per liter u/l, iii. d-dimers \> reference range, or iv. c-reactive protein (crp) \> 40 milligram per liter (mg/l). 6. subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.

inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at time of screening who is being treated for covid-19. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (chest x-ray, computed tomography (ct) scan, etc.). 4. pao2/fio2 ratio \> 300 to ≤ 450 mmhg (i.e., arterial oxygen in mmhg divided by fraction inspired oxygen concentration \[e.g., 0.21 for room air\]) 5. any one of the following related to covid-19: i. ferritin \> 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) \> 300 units per liter u/l, iii. d-dimers \> reference range, or iv. c-reactive protein (crp) \> 40 milligram per liter (mg/l). 6. subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.

inclusion criteria: hospitalized male or female subject ≥ 18 years of age at time of screening who is being treated for covid-19. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. covid-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (chest x-ray, computed tomography (ct) scan, etc.). pao2/fio2 ratio > 300 to ≤ 450 mmhg (i.e., arterial oxygen in mmhg divided by fraction inspired oxygen concentration [e.g., 0.21 for room air]) any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter u/l, iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.

inclusion criteria: hospitalized male or female subject ≥ 18 years of age at time of screening who is being treated for covid-19. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. covid-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (chest x-ray, computed tomography (ct) scan, etc.). pao2/fio2 ratio > 300 to ≤ 450 mmhg (i.e., arterial oxygen in mmhg divided by fraction inspired oxygen concentration [e.g., 0.21 for room air]) any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter u/l, iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.

inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at time of screening who is being treated for covid-19. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (chest x-ray, computed tomography (ct) scan, etc.). 4. pao2/fio2 ratio > 300 to ≤ 450 mmhg (i.e., arterial oxygen in mmhg divided by fraction inspired oxygen concentration [e.g., 0.21 for room air]) 5. any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter u/l, iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). 6. subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.

inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at time of screening who is being treated for covid-19. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (chest x-ray, computed tomography (ct) scan, etc.). 4. pao2/fio2 ratio > 300 to ≤ 450 mmhg (i.e., arterial oxygen in mmhg divided by fraction inspired oxygen concentration [e.g., 0.21 for room air]) 5. any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter u/l, iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l). 6. subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.